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Acute hemolytic transfusion reaction 
attributed to anti-Ata
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Case repOrt
Anti-Ata is a rare alloantibody that can be clinically significant. 
We report a case of a woman who, after emergency-released 
uncrossmatched red blood cell transfusion, experienced an 
acute hemolytic transfusion reaction attributed to anti-Ata. The 
case presented herein highlights the importance of recognizing 
that anti-Ata may indeed cause acute hemolytic reactions. 
Immunohematology 2016;32:140–142.
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Anti-Ata is directed at the Ata (Augustine) antigen, a high-
prevalence red blood cell (RBC) antigen present in greater 
than 99 percent of people in all populations.1 Individuals 
lacking the Ata antigen, who can potentially make anti-
Ata, often originate from the Caribbean or Southern United 
States.1 The Ata antigen and corresponding antibody were 
first described by Applewhaite and colleagues in 1967 after a 
weakly positive direct antiglobulin test (DAT) was incidentally 
discovered in an infant of a multiparous black woman of West 
Indian origin named Mrs. August.2 There was no laboratory or 
clinical evidence of hemolytic disease of the fetus and newborn 
(HDFN) during any of her three pregnancies. Subsequent 
population analyses have demonstrated reactivity of anti-Ata 
with RBCs of at least 6600 random New Yorkers (including 
at least 2200 individuals of African ancestry),2 at least 3000 
random blood donors,3 and 8551 out of 8552 people living in 
Detroit, Michigan, of African ancestry4—thus establishing the 
high prevalence of Ata.
There have been several published reports describing anti-
Ata, totaling 14 patients in all, but only a subset of these patients 
have experienced an adverse reaction after RBC transfusion 
attributed to anti-Ata (Table 1). The reported adverse reactions 
Table 1. Reported cases of anti-Ata





12 Female Unknown Black B No Yes DAT+ in newborn
23 Female 40 Black A No Yes No
35 Male 65 Black O Yes — Chills
45 Female 26 Black O No Yes No
55 Female 34 Black AB Yes Yes No
65 Female 39 Black B No Yes Unknown
75 Female 44 Black B Unknown Yes DAT+ in newborn
85 Female 35 Black B No Yes No
96 Female Unknown Black B Unknown Yes DAT+ in newborn; decreased 24-hour RBC survival 
study (2 mL)
107 Female 26 Black O Yes No Fever, chills, nausea associated with decreased 3- and 
19-hour RBC survival study (5 mL)
117 Female 36 Black A No Yes DAT+ in newborn
128 Female 35 Black A Unknown Yes HDFN
139 Female 60 Black Unknown No Yes DHTR
1410 Female 37 Black AB No Yes No
15* Female 40 Black O No Yes AHTR
*Patient described in the current report.
DAT = direct antiglobulin test; RBC, red blood cell; HDFN = hemolytic disease of the fetus and newborn; DHTR = delayed hemolytic transfusion reaction; 
AHTR = acute hemolytic transfusion reaction.
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Acute HTR attributed to anti-Ata
in this population include positive DAT in newborns,2,5,6 
chills,5,7 fever,7 nausea,7 decreased RBC survival,6,7 a moderate 
case of HDFN,8 and, most recently, a case of severe delayed 
hemolytic transfusion reaction.9 Nonetheless, until now, 
no acute hemolytic transfusion reaction associated with 
transfusion of an At(a+) RBC unit has been described. We 
report a case in which a clinically significant acute hemolytic 
transfusion reaction was attributed to anti-Ata.
Materials and Methods
All data were retrospectively collected from the patients’ 
medical records. This review was approved by the Quality 
Council of the Institute for Transfusion Medicine (Pittsburgh, 
PA). ABO and D testing were performed using solid-phase 
technology (Galileo, Immucor, Inc., Norcross, GA). All 
additional immunohematology testing was performed using 
saline tube methods with reactions graded on a scale of 0 to 4+. 
Additional reagents used included low-ionic-strength saline 
(LISS), polyspecific (anti-IgG/anti-C3d) antihuman globulin 
(AHG), monospecific anti-IgG AHG, monospecific anti-C3d 
AHG, and acid elution kit (all obtained from Immucor, Inc.).
Case Report
A 40-year-old black woman with history of autoimmune 
hypothyroidism, three uneventful pregnancies, and no history 
of transfusion presented with fatigue and dyspnea on exertion. 
Her symptoms were secondary to megaloblastic anemia 
and severe vitamin B12 deficiency attributable to pernicious 
anemia that was positive for anti-intrinsic factor antibody. Her 
admission laboratory values included: hemoglobin 5.6 g/dL 
(normal 12.3–15.3 g/dL), platelet count 80,000/µL (normal 
145,000–445,000/µL), lactate dehydrogenase (LDH) 4440 
IU/L (normal 110–216 IU/L), total bilirubin 3.7 mg/dL (normal 
0.2–1.2 mg/dL), and direct bilirubin 0.8 mg/dL (normal 0.0–0.4 
mg/dL). Her ABO and D typings showed her RBCs to be group 
O, D+. Her antibody screen was positive, with all screening 
cells reacting 3+ at the AHG phase in tube testing with LISS 
enhancement. Because of her positive antibody screen, a DAT 
was performed, and it was negative with polyspecific AHG 
reagent; an eluate was performed and was also negative. Because 
of the patient’s symptomatic anemia, the decision was made to 
emergently transfuse the patient, and two emergency-released 
uncrossmatched RBC units were issued. Approximately 15 
minutes after the first RBC unit had been completely transfused, 
the patient developed chills and had one episode of dark urine, 
although she remained afebrile with stable vital signs.
A transfusion reaction workup was initiated. All elements 
of the clerical check were confirmed normal; these elements 
consisted of verification of (1) the blood bank issuing the 
proper blood product to the proper patient, (2) the unit number 
on the blood unit matching the unit number on the transfusion 
reaction form, (3) documentation of health care personnel 
having double-checked patient identification and blood product 
information prior to transfusion of the blood unit to the proper 
patient, and (4) patient identification on the post-transfusion 
blood sample and transfusion reaction form matching the 
blood bank records. Both the pre-transfusion and post-
transfusion plasma specimens were icteric on visual inspection 
with no hemolysis noted. Biochemical tests of hemolysis were 
positive, including increased LDH (5669 IU/L), increased total 
bilirubin (7.1 mg/dL), increased direct bilirubin (2.2 mg/dL), 
and haptoglobin less than 10 mg/dL (normal 16–200 mg/dL). 
Repeat hemoglobin measurement demonstrated no post-
transfusion increase from her pre-transfusion concentration 
(5.4 mg/dL). The DAT was now found to be weakly positive 
with polyspecific AHG reagent, negative with anti-C3d 
reagent, and weakly positive with anti-IgG AHG reagent. The 
eluate reacted with all screening cells at AHG phase (2+) except 
for the autocontrol. These findings suggested an alloantibody 
to a high-prevalence antigen had been detected, and anti-Ata 
was subsequently identified by a large immunohematology 
reference laboratory (Immunohematology Reference 
Laboratory, LifeShare Blood Centers, Shreveport, LA). The 
patient’s RBCs were serologically typed for Ata and found to be 
negative. A differential adsorption using human erythrocyte 
stroma prepared from R1R1, R2R2, and rr cells of known 
phenotype was performed on the patient’s serum to rule out 
the presence of any other underlying alloantibodies; none were 
identified. Two At(a–) RBCs units were obtained (one frozen 
unit immediately available from internal RBC inventory and 
one frozen unit available from regional blood donor center 
within 48 hours of request via the American Rare Donor 
Program), crossmatched, transfused without incident, and 
appropriately increased her hemoglobin level (pre-transfusion 
value 6.9 g/dL to post-transfusion value 8.9 g/dL).
Discussion
This case report describes a rare alloantibody, anti-Ata, 
which was implicated as a cause of a clinically significant 
acute hemolytic reaction. Immunohematology data from 
previous reports of anti-Ata have described it to be detectable 
with polyspecific and/or anti-IgG AHG reagents when bound 
to RBCs,2,3,5,6,8–11 and in the vast majority of cases there has 
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been no complement bound to the RBCs as detected using 
routine anti-C3d monospecific AHG reagent.1,8 The in vitro 
immunohematologic characteristics of anti-Ata described 
in this current report are consistent with those previously 
reported. Autoimmune disease has been posited7 as having 
an association with development of anti-Ata—this proposed 
relationship is supported by the patient in the current report, 
who has two autoimmune diseases.
Recently, the genetic basis for the At(a–) phenotype 
has been discovered: a non-synonymous single nucleotide 
polymorphism in rs45458701 (c.1171G>A in exon 12 of 
SLC29A1) resulting in a non-conservative p.Glu391Lys 
substitution.12 This finding has the potential to identify At(a–) 
donors and patients via RBC genotyping studies. Based on 
this evidence, the Augustine blood group system was formed 
(symbol AUG), and the Ata antigen was named AUG2 (number 
036002).13
In conclusion, although anti-Ata is a rare antibody of 
variable clinical significance, it has the potential to cause rapid, 
acute, clinically significant hemolysis. If possible, patients who 
develop anti-Ata and require RBCs should be transfused with 
units negative for the cognate antigen.
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